Pneumonia, Pneumocystis
8
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (8)
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Pneumocystis Pneumonia Diagnosis in HIV- Patients
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
Specialized Proresolving Mediators in Pneumocystis Jirovecii Pneumonia
Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19
Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19
Spirulina Supplementation and Infant Growth, Morbidity and Motor Development
Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients